What is AB Science?
Founded in 2001 and headquartered in Paris, AB Science specializes in the research and development of protein kinase inhibitors designed to address significant unmet medical needs. The company maintains a robust portfolio of molecules, with its lead compound, masitinib, already established in veterinary medicine and currently undergoing rigorous evaluation for human therapeutic applications. By targeting inflammatory, viral, and neurological diseases, AB Science occupies a specialized niche in the biotechnology landscape, leveraging its public listing on Euronext Paris to sustain long-term R&D initiatives across Europe and North America.
How much funding has AB Science raised?
AB Science has raised a total of $48M across 8 funding rounds:
Share Placement
$18.3M
Debt
$7.2M
Debt
$8.5M
Stock/Share Issuance
$2M
Stock/Share Issuance
$3.2M
Multiple Rounds
$8.8M
Share Placement (2020): $18.3M with participation from Undisclosed
Debt (2021): $7.2M led by Societe Generale, Banque Populaire Group, and Bpifrance
Debt (2022): $8.5M, investors not publicly disclosed
Stock/Share Issuance (2025): $2M, investors not publicly disclosed
Stock/Share Issuance (2025): $3.2M, investors not publicly disclosed
Stock/Share Issuance (2026): $3.7M, investors not publicly disclosed
Private Equity (2026): $3M, investors not publicly disclosed
Private Equity (2026): $2M, investors not publicly disclosed
Key Investors in AB Science
Societe Generale
A French-based multinational financial services company founded in 1864, providing comprehensive retail, private banking, and insurance solutions.
Bpifrance
A French public investment bank that supports the growth of companies through credit, guarantees, and equity financing at every stage of development.
Banque Populaire Group
A major French banking group providing a wide range of financial services and strategic capital support to domestic enterprises.
What's next for AB Science?
With the recent injection of capital, AB Science is positioned to accelerate its clinical trial pipeline and expand its operational footprint. The strategic focus will likely remain on the advancement of masitinib and the diversification of its kinase inhibitor library. As the company transitions through this phase of enterprise-level growth, stakeholders will be monitoring the regulatory milestones and potential commercialization timelines for its human-focused medical applications. The firm's ability to maintain its trajectory in a highly competitive pharmaceutical market will depend on its continued success in securing both public and private financing to support its intensive research requirements.
See full AB Science company page
